- Home
- / Lyra Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Lyra Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.3
2024-10-29
Market Capitalization
$17.4 M
2024-10-29
Revenue
$398 K
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 285.0K | 1.4M | 1.6M | 1.5M | 398.0K | |
| General and administrative expense | 9.7M | 14.2M | 17.6M | 19.1M | 18.5M | 11.5M |
| Operating expense total | 22.2M | 56.4M | 62.3M | 30.0M | ||
| EBIT | (22.2M) | (43.6M) | (56.3M) | (67.1M) | (96.3M) | (31.0M) |
| EBIT margin, % | -4131.0% | -6280.8% | -7794.5% | |||
| Interest income | 82.0K | 102.0K | 1.0M | 4.5M | 3.0M | 1.1M |
| Pre tax profit | (55.3M) | (62.6M) | (93.4M) | (28.9M) | ||
| Income tax expense | 13.0K | 59.0K | 39.0K | 11.0K | ||
| Net Income | (22.1M) | (43.5M) | (55.3M) | (62.7M) | (93.4M) | (28.9M) |
| EPS | (1.8) | (1.0) | (1.4) | (18.6) |